Exelixis Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Exelixis Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Alameda
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
January
Ticker symbol
EXEL
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000939767
EIN
04-3257395

Board of directors

Follow this board

Chief executives

Michael Morrissey · President and CEO
Dates unknown

Director election results

Annual meeting of May 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 16 other boards.

Network of Exelixis Inc.'s board connections Alexandria Real Estate Equities Inc. Alexandria Real Estate... Becton Dickinson and Company Becton Dickinson and C... Biogen Inc. Biogen Inc. Caris Life Sciences Inc. Caris Life Sciences In... Huntsman Corporation Huntsman Corporation Invivyd Inc. Invivyd Inc. Johnson & Johnson Johnson & Johnson Legend Biotech Corporation Legend Biotech Corpora... Liquidia Corporation Liquidia Corporation Ovid Therapeutics Inc. Ovid Therapeutics Inc. SiteOne Landscape Supply Inc. SiteOne Landscape Supp... Stoke Therapeutics Inc. Stoke Therapeutics Inc... Vera Therapeutics Inc. Vera Therapeutics Inc. Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals... Xilio Therapeutics Inc. Xilio Therapeutics Inc... nVent Electric plc nVent Electric plc Alan M. Garber Alan M. Garber David Edward Johnson David Edward Johnson George Poste George Poste Jack L. Wyszomierski Jack L. Wyszomierski Jacqueline Wright Jacqueline Wright Julie Smith Julie Smith Maria C. Freire Maria C. Freire Mary C. Beckerle Mary C. Beckerle Michael Morrissey Michael Morrissey Stelios Papadopoulos Stelios Papadopoulos Exelixis Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$1,187,180
1 purchase by 1 insider
Sold, last 12 months
$42,242,344
32 sales by 12 insiders
Date Insider Transaction Shares Price Value
Aug 10, 2026 Mary C. Beckerle Director Open-market sale −9,812 $53.66 $526,512
Jun 1, 2026 Jack L. Wyszomierski Director Open-market sale −3,925 $50.55 $198,409
Jun 1, 2026 Sue Gail Eckhardt Director Open-market sale −9,812 $50.14 $491,974
May 27, 2026 Stelios Papadopoulos Director Grant or award +8,367 — —
May 27, 2026 Tomas J. Heyman Director Grant or award +8,367 — —
May 27, 2026 Sue Gail Eckhardt Director Grant or award +8,367 — —
May 27, 2026 Julie Smith Director Grant or award +8,367 — —
May 27, 2026 Maria C. Freire Director Grant or award +8,367 — —
May 27, 2026 Mary C. Beckerle Director Grant or award +8,367 — —
May 27, 2026 Bob Oliver Director Grant or award +8,367 — —
May 27, 2026 Jack L. Wyszomierski Director Grant or award +8,367 — —
May 27, 2026 George Poste Director Grant or award +8,367 — —
May 26, 2026 Aftab Dana Officer (EVP, Research and Development) Open-market sale −43,451 $50.35 $2,187,758
May 20, 2026 Haley Patrick J. Officer (EVP, Commercial) Open-market sale −32,110 $49.81 $1,599,399
May 18, 2026 Michael Morrissey Director, Officer (President and CEO) Gift −124,047 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.